Abbvie ((ABBV)), Genmab (Otc) ((GMAB)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie and Genmab are conducting a Phase 1b/2 clinical study to evaluate the safety and tolerability of epcoritamab, a subcutaneous investigational drug, in combination with various anti-neoplastic agents for treating Non-Hodgkin Lymphoma (NHL). The study aims to assess adverse events and changes in disease activity among approximately 565 adult participants globally.
The study involves several experimental treatment arms, each testing different combinations of epcoritamab with oral and intravenous drugs like lenalidomide, ibrutinib, and polatuzumab vedotin, targeting various forms of NHL, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).
This interventional study follows a non-randomized, sequential model with no masking, primarily focusing on treatment. It started on June 14, 2022, with the last update submitted on August 4, 2025, and is currently recruiting participants.
The ongoing study could significantly impact AbbVie and Genmab’s market positions, potentially boosting investor confidence if successful. This development is crucial given the competitive landscape in the oncology sector.
The study is ongoing, and further details are available on the ClinicalTrials portal.